VistaGen Therapeutics (VTGN) Misses Q1 EPS by 8c

VistaGen Therapeutics (NASDAQ: VTGN) reported Q1 EPS of ($0.94), $0.08 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $170 thousand versus the consensus estimate of $184.6 thousand.

For earnings history and earnings-related data on VistaGen Therapeutics (VTGN) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Can global equities keep rising? UBS sees these factors driving upside
• Corpay agrees to $100M FTC settlement over marketing practices